Alzheimer’s Disease (AD) is a progressive and irrevocable neurodegenerative disease. It slowly affects brain tissue and provokes irrevocable motor and psychological functions loss.
AD mild symptoms usually first manifest in individuals as much as 8 years before they are officially diagnosed with the disease. Short-term memory loss, difficulty to accomplish complex tasks, problems with semantic memory and understanding are the most common of the pre-dementia symptoms.
Following those mild cognitive deficits, language deficit, motor dysfunction, agnosia and apraxia then confirm the diagnosis.
AD doesn’t affect all individuals the same way and symptoms frequency and severity is evaluated on a case-by-case basis.
Alzheimer’s Disease patients’ brains suffer both a degeneration and inflammation process. At the extracellular level within the brain, Beta-amiloïd epeptide starts to accumulate and form what is characteristically referred to as “plaque”. At the same time, Tau protein accumulates inside brain cells and provoke the formation of neurofibrils.
Progressively, a loss of neurons and synapsis in the cortex is observed, which causes the affected brain regions to retract (atrophia).
Tg models for in vitro studies
Our brain slice electrophysiology platform successfully showed that Tg mice display electrophysiological properties deficits compared to their wild type counterparts. As an expert in electrophysiological studies, we can study your compound’s efficacy on such models.
iPSC-derived neurons from AD patients
in vivo models
Our member OptoPath, a rodent platform entirely dedicated to innovation in experimental psychopathology, provides behavioral test to assess impairments characteristic of AD:
Our preferred partner KEY-OBS, preclinical CNS CRO specialized in in vivo models of neurological disorders, has developed models simulating closely Alzheimer’s Disease symptoms.
Please contact us for more information on our available AD models and assays.
